** Shares of cancer drug developer Lantern Pharma rise ~15% to $3.63 premarket
** LTRN says the U.S. Food and Drug Administration has granted "fast track" designation to its experimental drug to treat a type of breast cancer called triple negative breast cancer (TNBC)
** The drug, LP-184, showed preclinical efficacy in treating TNBC - LTRN
** FDA's "fast track" status expedites the review of medicines to treat serious conditions
** As of last close, stock has fallen 26.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。